α-Synuclein & Lewy Bodies

1. SNCA and the Discovery of α-Synuclein

The story of α-synuclein(encoded by SNCA on chromosome 4q22) begins in 1988, when Maroteaux and Scheller isolated a novel synaptic protein from Torpedo electric organ and named it “synuclein” for its dual presence in synaptic terminals and the nucleus. In 1993 Ueda and colleagues identified a fragment they called NAC (non-amyloid-β component) within Alzheimer plaques and traced it to the same protein.

The connection to PD was made in 1997 by Mihael Polymeropoulos and colleagues (Science 1997; Mutation in the α-synuclein gene identified in families with Parkinson’s disease): a missense mutation A53T in SNCA co-segregated with autosomal-dominant PD in the Italian Contursi kindred and a Greek-American family. Within a year (Spillantini and Goedert, Nature 1997; α-synuclein in Lewy bodies), α-synuclein was shown to be the principal aggregated component of Lewy bodies in sporadic PD — uniting Mendelian and idiopathic disease around a single molecule. SNCA duplications and triplications later showed that gene dosage alone, without any sequence change, suffices to cause autosomal-dominant PD (Singleton et al., Science 2003), establishing the principle that α-synuclein concentration is a disease driver in its own right.

2. Structure — Intrinsic Disorder Becomes Cross-β

α-synuclein is a 140-amino-acid protein with three regions:

• N-terminal amphipathic domain (1–60) — seven imperfect 11-residue repeats with a KTKEGV motif. Folds into amphipathic α-helix on contact with anionic membranes (phosphatidylserine, cardiolipin). Houses all known autosomal-dominant PD missense mutations: A30P, E46K, H50Q, G51D, A53T, A53E.
• NAC region (61–95) — hydrophobic core; the obligate amyloidogenic segment. Cross-β spine of fibrils maps here.
• C-terminal acidic tail (96–140) — highly negatively charged; intrinsically disordered; site of post-translational modifications (Ser-129 phosphorylation, truncation, nitration, ubiquitination).

In solution, α-synuclein is intrinsically disordered with no stable tertiary structure (Weinreb et al., Biochemistry 1996). On membranes it adopts an extended amphipathic α-helix; in detergent micelles it folds into a horseshoe of two helices. Whether the physiological cytosolic species is monomeric or tetrameric is debated (Bartels et al., Nature 2011 vs Burré et al., Nature 2013), but the consensus is that membrane-binding shifts the conformational ensemble dramatically.

When α-synuclein aggregates, the disordered chain refolds into a stacked cross-β structure: parallel in-register β-strands run perpendicular to the fibril axis, with each monomer contributing one rung to the β-sheet ladder. The cryo-EM structures of recent years (PDB 6CU7, 6H6B, 6XYO, 6OSL) define multiple polymorphic architectures — the “rod” and “twister” folds of recombinant fibrils, and the distinct fold seen in brain-derivedMSA filaments (Schweighauser et al., Nature 2020).

3. The Physiological Function

Despite ~30 years of work, the physiological role of α-synuclein remains partially defined. The most consistent findings:

• Presynaptic localisation — α-synuclein is highly enriched at presynaptic terminals, where it binds synaptic vesicles via its N-terminal helices.
• SNARE complex chaperoning — Burré et al. (Science 2010) showed α-synuclein binds VAMP2/synaptobrevin and facilitates SNARE assembly, supporting vesicle fusion.
• Vesicle pool dynamics — α-synuclein clusters synaptic vesicles and may regulate the recycling pool size; over-expression depresses neurotransmission, knock-out modestly elevates dopamine release.
• Membrane curvature sensing — the amphipathic helix preferentially binds curved, anionic vesicles, especially mitochondria-associated membranes (MAMs).
• Lipid metabolism & mitochondrial contact — emerging links to lipid trafficking via interactions with phospholipase A2, glucocerebrosidase (GCase, GBA), and mitochondrial cardiolipin.

Triple-knockout mice lacking all three synucleins (α, β, γ) are viable but show age-dependent synaptic dysfunction (Greten-Harrison et al., PNAS 2010), suggesting redundant chaperone-like roles. The disease state is therefore not loss of function but toxic gain-of-functionfrom misfolded oligomers and fibrils.

4. Aggregation Pathway — from Monomer to Fibril

α-synuclein aggregation follows a nucleation-elongation kinetic scheme, quantitatively dissected by the Knowles, Dobson and Vendruscolo groups (Nat Chem 2014; PNAS 2016). The reaction has three rate steps:

\[ n\,A_1 \;\xrightleftharpoons[k_{-n}]{k_n}\; A_n \quad \text{(primary nucleation, slow)} \]

\[ A_n + A_1 \;\xrightarrow{k_+}\; A_{n+1} \quad \text{(elongation)} \]

\[ \frac{dM(t)}{dt} \;=\; k_+ M(t)\,m(t) \;+\; k_2\,M(t)\,m(t)^{n_2} \quad \text{(secondary nucleation)} \]

• Primary nucleation — rare, slow; rate-limiting in fresh monomer solutions. Produces a sigmoidal lag phase.
• Elongation — fast addition of monomer onto fibril ends. Linear in fibril concentration.
• Secondary nucleation — the catalytic surface of existing fibrils generates new nuclei. This is the engine of self-propagation, and the reason a small “seed” of pre-formed fibrils (PFFs) eliminates the lag phase entirely.
• Off-pathway oligomers — soluble, possibly toxic species that do not lie on the fibril pathway; pore-like β-barrel oligomers (Chen et al., Nat Commun 2015) are a candidate proximal toxin.

Toxicity localises to oligomers, not mature fibrils, in most experimental paradigms (Winner et al., PNAS 2011). Oligomers permeabilise membranes (the “pore hypothesis” analogous to Aβ in AD), poison mitochondrial complex I, disrupt ER–Golgi trafficking, and activate microglia via TLR2/4. Mature fibrils are the seeds for spread; small soluble oligomers are the executioners.

5. Lewy Bodies and Lewy Neurites

Friedrich Lewy (1912, working in Alois Alzheimer’s Munich laboratory) described eosinophilic intracytoplasmic inclusions in the dorsal motor nucleus of the vagus and substantia innominata of parkinsonian brains. Tretiakoff (1919) confirmed them in the substantia nigra and named them “corps de Lewy”. By light microscopy a classical Lewy body is a spherical 8–30 μm inclusion with a dense eosinophilic core and a pale halo; on electron microscopy a tangle of 7–10 nm filaments. By immunohistochemistry — the diagnostic standard since 1997 — they are intensely positive for α-synuclein with phospho-Ser129 modification.

Modern correlative-light/electron microscopy by Shahmoradian and colleagues (Nat Neurosci 2019) re-examined Lewy-body composition and found that, beyond the fibrillar core, much of the body is composed of crowded membranous organelles — vesicles, mitochondria, lysosomes — embedded in an α-synuclein and lipid matrix. This challenges the old “pure protein aggregate” view and re-frames Lewy bodies as the end-state of catastrophic organellar dysfunction and proteostatic collapse, with α-synuclein as scaffold rather than sole constituent.

Lewy neurites are the axonal/dendritic counterparts — thread-like α-synuclein-positive structures that vastly outnumber Lewy bodies and account for most of the synuclein burden in early disease. They are the form most amenable to detection and the form most likely relevant to clinical dysfunction, since Lewy bodies themselves may be relatively inert end-states.

6. The Braak Staging of Parkinson’s Pathology

In 2003 Heiko Braak and colleagues (Neurobiol Aging 2003; Staging of brain pathology related to sporadic Parkinson’s disease) proposed an analogous six-stage staging for α-synuclein pathology in PD, based on systematic post-mortem mapping with thioflavin-S and α-synuclein immunohistochemistry. Strikingly, the trajectory is caudo-rostral: pathology begins in the brainstem and olfactory bulb, long before reaching the substantia nigra.

• Stage 1 — dorsal motor nucleus of the vagus (DMV), glossopharyngeal IX nucleus, and olfactory bulb / anterior olfactory nucleus. Clinically silent or producing hyposmia & constipation.
• Stage 2 — ascends through the pontine tegmentum: locus coeruleus (REM-sleep behaviour disorder), caudal raphe nuclei (depression), magnocellular reticular formation. Premotor.
• Stage 3 — substantia nigra pars compacta and the central amygdala. Threshold of clinical motor onset.
• Stage 4 — mesocortex, transentorhinal cortex, hippocampal CA2.
• Stage 5 — high-order association neocortex. Onset of PD dementia.
• Stage 6 — primary motor and sensory cortex. End-stage disease.

The Braak hypothesis explains a striking clinical observation: many of the non-motor features of PD (hyposmia, RBD, constipation, depression, autonomic dysfunction) appear years to decades before motor symptoms, corresponding to stages 1–2. Hyposmia in 90%, RBD in ~30–50%, constipation in ~70% precede motor onset. This gives a clinical window into prodromal PD that the MDS Research Criteria for Prodromal PD (Berg et al., Mov Disord 2015) attempt to formalise.

7. Prion-Like Spread — the Modern Synthesis

The Braak topographic gradient implied that α-synuclein pathology propagates. The decisive evidence came in two parallel lines:

• Host-to-graft transmission — Kordower, Olanow, and Brundin (Nat Med 2008) showed that fetal mesencephalic neurons transplanted into PD patients in the 1980s developed Lewy bodies after 14 years in the graft, despite being host-genetically unrelated. Pathology had spread cell-to-cell across the host–graft interface.
• PFF inoculation — Luk, Lee and colleagues (Science 2012; Nature 2013) injected pre-formed recombinant α-synuclein fibrils into wild-type mouse striatum and showed propagation along anatomically connected pathways, producing motor deficits and SNc neuron loss months later. The model has since been replicated in non-human primates and is a workhorse for therapeutic screening.

The molecular mechanism: misfolded α-synuclein seeds escape the donor cell (via exosomes, tunnelling nanotubes, or unconventional secretion), are taken up by connected neurons (LAG3, heparan sulfate, and TMEM16F have been proposed as uptake receptors), template misfolding of native cytosolic α-synuclein, and accumulate as new fibrils that can themselves seed further cells. The kinetics recapitulate the secondary-nucleation behaviour seen in vitro.

This is the same biophysical logic as the prion (PrP^Sc) hypothesis —protein-only templated misfolding — without the inter-individual transmissibility that defines clinical prion disease. Hence the term prion-like: the molecular mechanism is shared, the epidemiology is not. The same framework now applies to tau, Aβ, TDP-43, and Huntingtin, making proteopathic seed-templating the unifying concept of neurodegeneration (Goedert, Science 2015).

8. The Gut–Brain Axis — the Vagal Hypothesis

Braak stage 1 includes the dorsal motor nucleus of the vagus (DMV) and the olfactory bulb. These two structures share an important property: they are exposed to the external environment via mucosal surfaces. Braak proposed (Neurosci Lett 2006) that an unidentified pathogen or environmental insult might enter through the nasal mucosa or the gut, seed local enteric or olfactory neurons, and ascend transsynaptically up the vagus to the brain.

Three lines of evidence support the gut-first hypothesis in a subset of patients:

• α-synuclein pathology in enteric neurons — described in colonic biopsies of PD patients years before motor onset (Shannon et al., Mov Disord 2012; Sampson et al., Cell 2016).
• Vagotomy reduces PD risk — a Danish national cohort (Svensson et al., Ann Neurol 2015) found that truncal vagotomy >20 years prior reduced PD incidence by ~40%, while super-selective vagotomy did not. A Swedish replication followed (Liu et al., Neurology 2017).
• Gut-to-brain spread in animal models — Kim, Mao and Dawson (Neuron 2019) showed that PFF injection into the duodenal/pyloric muscularis reaches the DMV and ascends to the SNc within 7–10 months in mice; vagotomy abolishes spread.
• Gut microbiota differences — PD patients show altered gut microbiomes (reduced Prevotellaceae, increased Enterobacteriaceae); germ-free SNCA-overexpressing mice show attenuated motor deficits compared with conventionally housed (Sampson et al., Cell 2016).

Borghammer and Van Den Berge (npj Parkinsons Dis 2021) have proposed a two-subtype model: a body-first phenotype (autonomic and RBD onset, gut/brainstem origin, symmetric, often DLB-leaning) versus a brain-first phenotype (motor onset, direct nigral seeding, asymmetric, classic PD). The model awaits validation but already shapes how SAA findings (skin, CSF, gut) are interpreted.

9. Fibril Polymorphism and Synucleinopathy “Strains”

Cryo-EM has revealed that α-synuclein fibrils are not a single structural species but a polymorphic familyof distinct folds, analogous to prion strains in scrapie. Brain-derived filaments from multiple system atrophy (MSA)show a fold (Schweighauser et al., Nature 2020) distinct from recombinant fibrils, and those from PD/DLB cortex show yet another. Differences in the cross-β core architecture, in the N- and C-terminal disposition, and in the number of protofilaments translate into different seeding behaviour, different cellular tropism, and ultimately different clinical syndromes.

• PD/DLB strain — targets neurons; produces Lewy-body morphology; predominantly limbic/cortical spread.
• MSA strain — targets oligodendrocytes (glial cytoplasmic inclusions, GCIs) preferentially; aggressive spread via white matter.
• Pure autonomic failure — restricted peripheral autonomic spread.

The strain concept has therapeutic implications: an antibody or small molecule that recognises one polymorph may not engage another; a SAA assay tuned to PD seeds may under-detect MSA. The “synucleinopathy spectrum” now spans a family of diseases with shared molecule, distinct molecular conformations, and distinct clinical syndromes.

The genetic architecture that drives some of this variation is the subject of Part IV (Genetics); the clinical phenotypes are mapped in Part V; the diagnostic translation (skin/CSF SAA, DaTscan) in Part VI; and the therapeutic pipeline targeting α-synuclein in Part VIII.